Contemporary cardiometabolic and anti-inflammatory therapies

Contemporary cardiometabolic and anti-inflammatory therapies lower the risk of strict 3-point major adverse cardiovascular events in humans (HR 0.83, 95% CI 0.80–0.86).

“10 trials involving 98,973 participants and 9,067 events yielded a consistent pooled estimate with no observed heterogeneity (HR 0.83, 95% CI 0.80–0.86; I2=0%).”

ReviewSensitivity analysis restricted to cardiovascular death, nonfatal myocardial infarction, and nonfatal stroken = 98,973

Contemporary cardiometabolic and inflammation targeting therapies reduce residual cardiovascular risk in an endpoint harmonized meta analysis

Scientific reports·15 Oct 2026

Contemporary cardiometabolic and anti-inflammatory therapies lower the risk of endpoint-harmonized major adverse cardiovascular events in humans (HR 0.84, 95% CI 0.79–0.88).

“Active therapy was associated with a lower risk of MACE than control (HR 0.84, 95% CI 0.79–0.88; I2=51%).”

ReviewPooled randomized trials comparing active therapy with controln = 157,278

Contemporary cardiometabolic and inflammation targeting therapies reduce residual cardiovascular risk in an endpoint harmonized meta analysis

Scientific reports·15 Oct 2026